Xencor Company Profile (NASDAQ:XNCR)

About Xencor (NASDAQ:XNCR)

Xencor logoXencor, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on discovering and developing engineered monoclonal antibodies to treat severe and life threatening diseases. It has developed two clinical-stage product candidates, using its Immune Inhibitor Fc platform: XmAb5871, which is in two Phase II trials and is being developed for autoimmune disease, and XmAb7195, which is in a Phase I trial and is being developed for asthma and allergic diseases. It is also developing a pipeline of bispecific antibody candidates using its heterodimer Fc bispecific technology: XmAb14045, which is in a Phase I trial for the treatment of acute myeloid leukemia (AML); XmAb13676, which is in a Phase I trial for the treatment of B-cell malignancies; XmAb18087, which is in preclinical development for the treatment of neuroendocrine tumors, and XmAb20717, which is in preclinical development for the treatment of various cancers and is its dual checkpoint inhibitor.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Bio Therapeutic Drugs
  • Sub-Industry: N/A
  • Symbol: NASDAQ:XNCR
  • CUSIP: N/A
  • Web: www.xencor.com
  • Market Cap: $961.04 million
  • Outstanding Shares: 46,926,000
Average Prices:
  • 50 Day Moving Avg: $22.80
  • 200 Day Moving Avg: $22.43
  • 52 Week Range: $18.45 - $29.38
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -11.91
  • P/E Growth: 0.00
Sales & Book Value:
  • Annual Revenue: $31.94 million
  • Price / Sales: 30.09
  • Book Value: $6.43 per share
  • Price / Book: 3.19
  • EBITDA: ($40,410,000.00)
  • Net Margins: -121.04%
  • Return on Equity: -13.79%
  • Return on Assets: -9.76%
  • Current Ratio: 1.96%
  • Quick Ratio: 1.96%
  • Average Volume: 169,855 shs.
  • Beta: 2.16
  • Short Ratio: 15.68

Frequently Asked Questions for Xencor (NASDAQ:XNCR)

What is Xencor's stock symbol?

Xencor trades on the NASDAQ under the ticker symbol "XNCR."

How were Xencor's earnings last quarter?

Xencor, Inc. (NASDAQ:XNCR) announced its quarterly earnings results on Monday, August, 7th. The company reported ($0.15) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.25) by $0.10. The firm earned $13.34 million during the quarter, compared to analyst estimates of $8.15 million. Xencor had a negative return on equity of 13.79% and a negative net margin of 121.04%. View Xencor's Earnings History.

Where is Xencor's stock going? Where will Xencor's stock price be in 2017?

5 analysts have issued 12-month price targets for Xencor's shares. Their predictions range from $21.00 to $36.00. On average, they expect Xencor's stock price to reach $28.00 in the next year. View Analyst Ratings for Xencor.

What are analysts saying about Xencor stock?

Here are some recent quotes from research analysts about Xencor stock:

  • 1. According to Zacks Investment Research, "Xencor Inc. is a clinical-stage biopharmaceutical company. It develops antibodies for the treatment of autoimmune diseases, asthma and allergic diseases, and cancer. Xencor Inc. is based in Monrovia, California. " (8/11/2017)
  • 2. Instinet analysts commented, "We are initiating on XNCR with a Neutral rating and a $21 target price. We recommend stepping to the sidelines in 2017, as we anticipate that XNCR shares will trade flat relative to the biotechnology index over the next 12 months. We note that several near-term catalysts are likely already 'baked in' the current valuation, particularly for the '5871 IgG4- RD program. We believe that a key catalyst'meaningful data for XNCR's bispecific assets'is likely to lead to upside, but that it will occur beyond our 12-month horizon." (3/1/2017)

Who are some of Xencor's key competitors?

Who are Xencor's key executives?

Xencor's management team includes the folowing people:

  • Bassil I. Dahiyat Ph.D., President, Chief Executive Officer, Founder, Director
  • John R. Desjarlais Ph.D., Senior Vice President, Research and Chief Scientific Officer
  • Paul Foster M.D., Senior Vice President, Chief Medical Officer
  • John J. Kuch, Vice President - Finance
  • Edgardo Baracchini Jr. Ph.D., Chief Business Officer
  • A. Bruce Montgomery M.D., Lead Independent Director
  • Kevin C. Gorman Ph.D., Independent Director
  • Kurt A. Gustafson, Independent Director
  • Yujiro S. Hata, Independent Director

Who owns Xencor stock?

Xencor's stock is owned by many different of institutional and retail investors. Top institutional investors include Nationwide Fund Advisors (0.13%). Company insiders that own Xencor stock include Bassil I Dahiyat, Bruce L A Carter, Edgardo Baracchini Jr, Edgardo Baracchini, Jr, John J Kuch, John R Desjarlais, John S Stafford III and Paul A Foster. View Institutional Ownership Trends for Xencor.

Who bought Xencor stock? Who is buying Xencor stock?

Xencor's stock was bought by a variety of institutional investors in the last quarter, including Nationwide Fund Advisors. View Insider Buying and Selling for Xencor.

How do I buy Xencor stock?

Shares of Xencor can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Xencor's stock price today?

One share of Xencor stock can currently be purchased for approximately $20.48.

MarketBeat Community Rating for Xencor (NASDAQ XNCR)
Community Ranking:  3.4 out of 5 (star star star)
Outperform Votes:  201 (Vote Outperform)
Underperform Votes:  98 (Vote Underperform)
Total Votes:  299
MarketBeat's community ratings are surveys of what our community members think about Xencor and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Consensus Ratings for Xencor (NASDAQ:XNCR) (How are Consensus Ratings Calculated?)
Ratings Breakdown: 2 Hold Ratings, 3 Buy Ratings
Consensus Rating:Buy (Score: 2.60)
Consensus Price Target: $28.00 (36.72% upside)
Consensus Price Target History for Xencor (NASDAQ:XNCR)
Price Target History for Xencor (NASDAQ:XNCR)
Analysts' Ratings History for Xencor (NASDAQ:XNCR)
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
10/23/2017Canaccord GenuitySet Price TargetBuy$36.00N/AView Rating Details
6/16/2017WedbushReiterated RatingOutperform$29.00LowView Rating Details
3/1/2017InstinetInitiated CoverageNeutral -> Neutral$21.00N/AView Rating Details
3/1/2017NomuraInitiated CoverageNeutralN/AView Rating Details
11/3/2016Leerink SwannReiterated RatingBuy$26.00N/AView Rating Details
10/4/2016Piper Jaffray CompaniesInitiated CoverageOverweight$35.00N/AView Rating Details
5/2/2016Oppenheimer Holdings, Inc.Reiterated RatingBuyN/AView Rating Details
12/22/2015FBR & CoReiterated RatingBuy$20.00N/AView Rating Details
(Data available from 10/23/2015 forward)


Earnings History for Xencor (NASDAQ:XNCR)
Earnings by Quarter for Xencor (NASDAQ:XNCR)
Earnings History by Quarter for Xencor (NASDAQ XNCR)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
8/7/2017Q2 2017($0.25)($0.15)$8.15 million$13.34 millionViewListenView Earnings Details
5/9/2017Q1 2017($0.25)($0.31)$8.15 million$4.34 millionViewListenView Earnings Details
8/2/2016Q216($0.18)$1.13$7.43 million$66.00 millionViewN/AView Earnings Details
5/2/2016Q116($0.27)($0.16)$3.50 million$7.30 millionViewN/AView Earnings Details
3/7/2016Q415($0.30)$0.19$2.50 million$21.80 millionViewN/AView Earnings Details
11/3/2015Q315($0.17)($0.25)$3.57 million$3.50 millionViewN/AView Earnings Details
8/4/2015Q215($0.18)($0.22)$1.90 million$1.01 millionViewN/AView Earnings Details
5/4/2015Q115($0.17)($0.19)$1.90 million$1.49 millionViewListenView Earnings Details
2/19/2015($0.22)($0.04)$1.33 million$5.66 millionViewN/AView Earnings Details
11/10/2014Q3 14($0.19)($0.20)$1.50 million$0.85 millionViewN/AView Earnings Details
7/31/2014($0.19)($0.16)$0.82 millionViewN/AView Earnings Details
5/14/2014Q1 14($0.16)($0.12)$1.71 million$2.20 millionViewN/AView Earnings Details
3/19/2014Q413($0.14)($0.24)$1.71 million$1.70 millionViewN/AView Earnings Details
(Data available from 1/1/2011 forward)


Earnings Estimates for Xencor (NASDAQ:XNCR)
2017 EPS Consensus Estimate: ($0.95)
2018 EPS Consensus Estimate: ($1.71)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20172($0.22)($0.17)($0.20)
Q2 20172($0.29)($0.19)($0.24)
Q3 20172($0.32)($0.23)($0.28)
Q4 20172($0.24)($0.24)($0.24)
Q1 20181($0.39)($0.39)($0.39)
Q2 20181($0.42)($0.42)($0.42)
Q3 20181($0.44)($0.44)($0.44)
Q4 20181($0.46)($0.46)($0.46)
(Data provided by Zacks Investment Research)


Dividend History for Xencor (NASDAQ:XNCR)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading and Institutional Ownership History for Xencor (NASDAQ:XNCR)
Insider Ownership Percentage: 4.03%
Institutional Ownership Percentage: 76.92%
Insider Trades by Quarter for Xencor (NASDAQ:XNCR)
Institutional Ownership by Quarter for Xencor (NASDAQ:XNCR)
Insider Trades by Quarter for Xencor (NASDAQ:XNCR)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
8/22/2017John S Stafford IIIMajor ShareholderBuy41,016$19.69$807,605.04View SEC Filing  
8/18/2017John S Stafford IIIMajor ShareholderBuy43,500$19.93$866,955.00View SEC Filing  
8/17/2017John S Stafford IIIMajor ShareholderBuy79,035$20.47$1,617,846.45View SEC Filing  
8/16/2017John S Stafford IIIMajor ShareholderBuy25,000$20.96$524,000.00View SEC Filing  
8/11/2017John S Stafford IIIMajor ShareholderBuy27,000$21.13$570,510.00View SEC Filing  
6/28/2017John S Stafford IIIMajor ShareholderBuy6,000$19.94$119,640.00View SEC Filing  
6/16/2017John S Stafford IIIMajor ShareholderBuy1,500$19.67$29,505.00View SEC Filing  
6/14/2017Bruce L A CarterDirectorSell20,000$20.61$412,200.00View SEC Filing  
6/2/2017Bruce L A CarterDirectorSell2,366$22.00$52,052.00View SEC Filing  
5/26/2017Bruce L A CarterDirectorSell12,400$22.19$275,156.00View SEC Filing  
5/2/2017Edgardo Baracchini JrInsiderSell10,568$26.01$274,873.68View SEC Filing  
4/27/2017Edgardo Baracchini JrInsiderSell904$26.04$23,540.16View SEC Filing  
3/16/2017John J. KuchVPSell15,000$24.42$366,300.00View SEC Filing  
3/8/2017Edgardo Baracchini JrInsiderSell1,821$25.00$45,525.00View SEC Filing  
12/6/2016John S Stafford IIIMajor ShareholderSell63,061$27.71$1,747,420.31View SEC Filing  
9/28/2016Edgardo Baracchini JrInsiderSell10,000$25.35$253,500.00View SEC Filing  
9/27/2016John S Stafford IIIMajor ShareholderSell40,000$25.72$1,028,800.00View SEC Filing  
9/2/2016Edgardo Baracchini JrInsiderSell10,000$21.06$210,600.00View SEC Filing  
8/30/2016Bassil I DahiyatInsiderSell40,000$21.80$872,000.00View SEC Filing  
8/26/2016John S Stafford IIIMajor ShareholderSell24,351$21.48$523,059.48View SEC Filing  
8/24/2016John J KuchVPSell25,000$21.95$548,750.00View SEC Filing  
8/23/2016John R DesjarlaisVPSell16,294$21.73$354,068.62View SEC Filing  
8/23/2016John S Stafford IIIMajor ShareholderSell96,828$21.73$2,104,072.44View SEC Filing  
8/16/2016Bassil I DahiyatInsiderSell45,886$22.06$1,012,245.16View SEC Filing  
8/15/2016Bruce L A CarterDirectorSell3,400$22.67$77,078.00View SEC Filing  
8/15/2016John S Stafford IIIMajor ShareholderSell10,000$23.06$230,600.00View SEC Filing  
8/11/2016John S Stafford IIIMajor ShareholderSell30,500$21.87$667,035.00View SEC Filing  
8/10/2016Edgardo Baracchini JrInsiderSell2,500$21.83$54,575.00View SEC Filing  
8/3/2016Edgardo Baracchini, Jr.InsiderSell4,528$20.00$90,560.00View SEC Filing  
8/3/2016John R. DesjarlaisVPSell5,905$20.00$118,100.00View SEC Filing  
7/11/2016Edgardo Baracchini JrInsiderSell1,250$18.13$22,662.50View SEC Filing  
6/28/2016Edgardo Baracchini JrInsiderSell1,250$15.10$18,875.00View SEC Filing  
5/24/2016Bassil I DahiyatCEOSell45,886$13.00$596,518.00View SEC Filing  
4/7/2016Edgardo Baracchini JrInsiderSell3,750$15.00$56,250.00View SEC Filing  
3/17/2016Bassil I DahiyatCEOSell45,886$11.02$505,663.72View SEC Filing  
3/3/2016John R DesjarlaisVPSell14,260$12.01$171,262.60View SEC Filing  
2/1/2016John S Stafford IIIMajor ShareholderSell25$10.79$269.75View SEC Filing  
1/29/2016John S Stafford IIIMajor ShareholderBuy25$10.83$270.75View SEC Filing  
1/4/2016John R. DesjarlaisVPSell1,100$14.13$15,543.00View SEC Filing  
12/17/2015John J KuchVPSell4,781$14.89$71,189.09View SEC Filing  
12/16/2015Paul A. FosterinsiderSell6,025$15.01$90,435.25View SEC Filing  
12/3/2015John S. Stafford IIIDirectorSell30,000$15.13$453,900.00View SEC Filing  
11/25/2015Edgardo Baracchini, Jr.insiderSell2,500$15.00$37,500.00View SEC Filing  
9/3/2015John S Stafford IIIDirectorSell10,000$17.22$172,200.00View SEC Filing  
9/1/2015Edgardo Baracchini, Jr.insiderSell1,250$16.49$20,612.50View SEC Filing  
7/6/2015John S Stafford IIIDirectorSell10,000$22.29$222,900.00View SEC Filing  
7/1/2015Edgardo Baracchini JrInsiderSell2,500$22.24$55,600.00View SEC Filing  
6/16/2015John S Stafford IIIDirectorSell20,000$20.35$407,000.00View SEC Filing  
6/15/2015Bruce L A CarterDirectorSell10,000$19.21$192,100.00View SEC Filing  
6/15/2015Edgardo Baracchini JrInsiderSell1,277$19.85$25,348.45View SEC Filing  
6/12/2015John J KuchVPSell8,756$19.35$169,428.60View SEC Filing  
6/12/2015John S Stafford IIIDirectorSell250,000$19.00$4,750,000.00View SEC Filing  
6/3/2015John S Stafford IIIDirectorSell10,000$18.76$187,600.00View SEC Filing  
6/1/2015Edgardo Baracchini JrInsiderSell1,250$18.14$22,675.00View SEC Filing  
5/26/2015John S Stafford IIIDirectorSell10,000$17.01$170,100.00View SEC Filing  
5/15/2015Edgardo Baracchini JrInsiderSell1,604$15.00$24,060.00View SEC Filing  
8/11/2014John S Stafford IIIDirectorSell124,000$9.37$1,161,880.00View SEC Filing  
12/6/2013John S Stafford IIIDirectorBuy275,000$5.50$1,512,500.00View SEC Filing  
(Data available from 1/1/2013 forward)


Headline Trends for Xencor (NASDAQ:XNCR)
Latest Headlines for Xencor (NASDAQ:XNCR)
Loading headlines, please wait.



Xencor (XNCR) Chart for Monday, October, 23, 2017

This page was last updated on 10/23/2017 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.